Brain-Targeting drug desipramine tested for IBS pain relief
NCT ID NCT00880594
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether desipramine, a medication that affects brain regions involved in pain processing, could help people with irritable bowel syndrome (IBS). Researchers planned to use brain scans to see how the drug changes pain signals in the brain. Only 18 people were enrolled, and the study was stopped early, so the findings are very limited.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Desipramine (a tricyclic antidepressant)
- What this could lead to
- If successful, this could point toward a treatment that reduces abdominal pain in IBS by altering how the brain processes pain signals.
- What could go wrong
- This was a very small, early study that was terminated before completion, so results are limited and may not apply to the broader IBS population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
18 people
The number who actually took part.
- Start date
-
Feb 2009
- Finished
-
Nov 2014
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 90 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * IBS subjects with- and without comorbid somatization features will be recruited from the sources highlighted above. * To be eligible, subjects will have to be between 18 and 90 years of age (inclusive) and qualify for a diagnosis of irritable bowel syndrome according to the criteria set forth in the Rome III criteria for the Diagnosis of Functional GI Disorders. * IBS patients will then be assessed in terms of comorbid somatization as determined using the Patient Health Questionnaire-15 (PHQ-15). * For this particular study, only subjects with high somatization (PHQ ≥ 10 or low somatization (PHQ ≤5) will be considered for enrollment. * Verification of somatization status will be performed using a formal structured interview process (Diagnostic Interview Schedule, DIS). * Persons are eligible to participate without regard to race or ethnicity. * Given sex differences in cerebral responses to noxious stimuli and the greater prevalence of IBS in women, only female participants will be sought in this study. * Also, in view brain hemispheric differences between left- and right-hand dominant individuals and the greater prevalence of right-handedness, all participants must be right-handed Exclusion Criteria: * Persons are excluded from participation for having various psychiatric, medical, and other characteristics. * Psychiatric/cognitive exclusions include any of the following: active suicidal or homicidal ideation or a history of attempted suicide, current excessive alcohol use or other substance abuse disorders, active major depression, anxiety disorder, bipolar depression or any psychotic disorder, unwillingness to be randomized or provide informed consent, inability to communicate with staff or significant cognitive impairment. * Medical and other exclusions include any of the following: renal or hepatic disease or impairment, diabetes, cardiovascular disease, cardiac arrythmia, cerebrovascular disease, or breastfeeding, pregnant, or imminent intention of pregnancy, history of seizures or primary neurological disorder, head trauma, brain damage, hyper- or hypothyroidism, history or abdominal surgery (other than cholecystectomy/appendectomy), or known structural GI disorder (Crohn's disease, etc.), contraindication to MRI (metallic implant, pacemaker), or rectal balloon distention (e.g., proctitis/colitis). * Exclusions related to medications: 1. Analgesics (narcotics, NSAIDs; acetaminophen OK) 2. Muscle relaxants 3. Psychoactive agents (antidepressants, antipsychotics) 4. Other medications (phenytoin; amphetamines, prescription weight-loss drugs, or benzodiazepines) 5. Thyroid medication 6. Anticholinergic medications or other IBS medications (hyoscyamine, dicyclomine) 7. Cytochrome p450 substrates 8. Participation in any clinical trial using any other drug.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Irritable bowel syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a website teach patients to tame gut pain and skip needless hospital tests?
- Could allergy pills calm irritable bowel syndrome?
- Can cutting certain carbs or gluten calm irritable bowel syndrome?
- Could a nickel allergy explain your Child's stomach pain?
- Ancient wisdom meets AI: could TCM features sharpen colorectal screening?
- Can cutting certain foods calm irritable bowel syndrome?